Uncategorized
IVERIC bio Announces Successful Advancement of LCA10 Minigene Program and Expansion of Orphan Gene Therapy Portfolio with USH2A-Related Inherited Retinal Diseases Program
NEW YORK--(BUSINESS WIRE)--IVERIC bio announced that the Company has entered into an exclusive global license agreement with the University of Massachusetts Medical School.